Keywords: Novartis, Onbrez, indactaterol, COPD

Novartis’ Onbrez Breezhaler significantly reduces COPD patient need for “relief” medication

Article | 19 May 2010

Print This

New analyses of data pooled from the indacaterol Phase III program for Swiss drug major’s Onbrez Breezhale brand of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in